Charles River Laboratories International, Inc. (NYSE:CRL) EVP Joseph W. Laplume Sells 4,400 Shares

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL traded up $0.86 during midday trading on Friday, hitting $163.11. The company’s stock had a trading volume of 1,215,947 shares, compared to its average volume of 1,060,465. The stock has a market capitalization of $8.34 billion, a price-to-earnings ratio of 1,087.39, a PEG ratio of 6.77 and a beta of 1.37. The stock’s 50 day simple moving average is $173.39 and its 200 day simple moving average is $188.81. Charles River Laboratories International, Inc. has a fifty-two week low of $150.79 and a fifty-two week high of $275.00. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same period last year, the business posted $2.46 earnings per share. The firm’s revenue was down 1.1% compared to the same quarter last year. As a group, research analysts anticipate that Charles River Laboratories International, Inc. will post 9.41 earnings per share for the current year.

Institutional Investors Weigh In On Charles River Laboratories International

A number of institutional investors have recently added to or reduced their stakes in CRL. Creative Planning grew its position in Charles River Laboratories International by 4.0% during the third quarter. Creative Planning now owns 4,672 shares of the medical research company’s stock worth $920,000 after buying an additional 180 shares in the last quarter. Blue Trust Inc. grew its position in Charles River Laboratories International by 28.6% during the third quarter. Blue Trust Inc. now owns 1,877 shares of the medical research company’s stock worth $388,000 after buying an additional 418 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in Charles River Laboratories International during the third quarter worth about $83,800,000. Riverwater Partners LLC grew its position in Charles River Laboratories International by 2.3% during the third quarter. Riverwater Partners LLC now owns 5,643 shares of the medical research company’s stock worth $1,089,000 after buying an additional 126 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its position in Charles River Laboratories International by 152.6% during the third quarter. Assenagon Asset Management S.A. now owns 49,030 shares of the medical research company’s stock worth $9,657,000 after buying an additional 29,621 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. TD Cowen increased their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. Bank of America cut their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Evercore ISI raised their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. Finally, StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $195.71.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).